Facebook
Twitter
Linkedin
Email
Print
Menu
What’s New
About Us
Overview
TBP Leadership
TBP Content Team
TBP Community
Submit to TBP
Health & Disease
History & Culture
Overview
Essays
Anthropology
Contemporary Culture
Gender and Sexuality
History of Medicine
Religion
Visual Arts
Poetry and Creative Writing
Art Interpretation
Blood Vessel Glass Sculpture Series
Did you know?
Podcasts
Book Reviews
Patient Experiences
Contact
Search
Algorithms and Flowcharts
Prev
1
/
0
Next
Prev
1
/
0
Next
Navigation
DAT, direct antiglobulin test; HA, hemolytic anemia; TMA, thrombotic microangiopathy; MAHA, macroangiopathic hemolytic anemia; SCD, sickle cell disease; HS, hereditary spherocytosis; HE, heredity elliptocytosis; PHN, paroxysmal nocturnal hemoglobinuria; Def, deficiency; PKD, pyruvate kinase deficiency. primary BM, primary bone marrow condition.
TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenia purpura, STEC-HUS, Shiga toxin-producing
Escherichia coli
hemolytic uremic syndrome
While TPE and steroids are the mainstay of TTP treatment, some experts recommend the inclusion of rituximab and/or caplacizumab under certain situations. Presence of ADAMTS13 inhibitor consistent with acquired autoimmune TTP, while their absence is suggestive of congenital TTP. Plasma infusion is usually sufficient to treat acute episodes in patients with hereditary TTP. According to ISTH guideline: continuing or stopping treatments (eg, TPE, corticosteroids, rituximab, caplacizumab) when plasma ADAMTS13 activity is between 10 and 20 IU/dL (or 10%−20% of normal) (an equivocal result). Abbreviations: TTP, thrombocytic thrombocytopenic purpura.
TTP, thrombotic thrombocytopenia purpura; TPE, therapeutic plasma exchange. From Semin Thromb Hemost. 2020;46:289-301.
Prev
1
/
0
Next